IGF2 (Insulin-like growth factor 2)

Finally, public data showed that H19 is more abundant in the EPN PF subgroup A, and that methylation of its imprinting control region (ICR) correlates strongly with better prognosis in EPN PF subgroup B (PFB). These findings suggest that H19 plays an oncogenic role in EPN and that the methylation status of its ICR may serve as a prognostic biomarker in PFB.

It is thought to occur secondary to the secretion of a prohormone of insulin-like growth factor II by the tumour. Here we describe the diagnosis and management of a rare case of seronegative DPS in a patient with a pleural-based SFT.

Our work uncovers a previously unrecognized PRKN-METTL3-CLDN2 signaling network that orchestrates colorectal tumorigenesis, providing a compelling rationale for developing METTL3-targeted therapies against CRC.

Early recognition is crucial to avoid serious complications. Complete surgical removal remains the cornerstone of effective management, while alternative therapies may be needed in inoperable cases.

A normal ACTH stimulation test can rule out AI assertively in such scenario. Further studies are needed to clarify the mechanisms of this discordance.

DC218 significantly degraded ECM, overcame lenvatinib resistance, and synergistically inhibited HCC. These findings provide mechanistic insight into the role of PLAGL2 in HCC ECM remodeling, as well as suggest a novel strategy for inhibiting ECM and treating HCC.

Gain of MYCN features uniquely in Asian patients and may represent a favorable prognostic marker. These results identify distinct molecular subgroups associated with varying prognosis and relapse among Asian patients.

P=N/A, N=96, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

When epigenetically disrupted, it enables tumors to reactivate developmental pathways that drive unchecked growth, EMT, metastasis, and resistance to apoptosis. Controlling the balance of imprinting of the H19/IGF2 locus presents a promising mechanism for future therapies.

This sensing of BUB1-regulated expression of the extracellular (dsRNA) and the stromal remodelling mediated by IGFL2 can be considered a pathogenic interface between DDR activation and the inflammatory response of the maladaptive immune response. These revelations ensure that BUB1 and IGFL2 are core immunoregulatory nodes upon which therapeutic actions are understood in accurate oncology, immunotherapy, and the control of autoimmune diseases.

Oncogenic MRs were recapitulated in 24 bulk RNA profiles, while 20 DNA profiles revealed recurrent IGF2/PI3K/AKT alterations, reinforcing shared transcriptional vulnerabilities. These findings characterize aberrant, mutant MYOD1-driven myogenesis sustained by IGF2 and nominate IGF1R-PI3K/AKT/mammalian target of rapamycin inhibitors for therapeutic translation in MYOD1L122R-mutant SRMS, underscoring the utility of single-cell regulatory network analysis for uncovering actionable dependencies in rare, transcriptionally complex cancers.

IMP3 expression is strongly associated with malignant histology and poorer overall survival in PTs; however, its independent prognostic value could not be conclusively established due to the limited number of outcome events. While IMP3 may serve as a promising marker in routine pathological assessment, validation in larger, prospective cohorts with sufficient event numbers is warranted.